Sage Therapeutics Income Statement

Financials in millions VND. Fiscal year is October - September.

Millions VND. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2016	FY 2015
Period Ending	Jun '25 Jun 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Dec '16 Dec 31, 2016	Jan '16 Jan 1, 2016
Revenue	117,027	123,962	169,125	384,512	9,741	3,675
Revenue Growth (YoY)	-8.67%	-26.70%	-56.02%	3847.45%	165.06%	-
Cost of Revenue	39,834	48,153	69,184	129,329	3,859	2,506
Gross Profit	77,192	75,809	99,940	255,183	5,882	1,169
Selling, General & Admin	14,286	20,165	28,389	86,732	2,610	936.02
Operating Expenses	14,286	20,165	28,389	86,732	2,610	936.02
Operating Income	62,906	55,643	71,551	168,450	3,272	232.83
Interest Expense	-43,701	-47,034	-52,944	-21,037	-104.42	-29.38
Interest & Investment Income	42.84	42.84	16,984	-	1.87	1.16
Earnings From Equity Investments	1,026	39.61	-	-	-	-
Other Non Operating Income (Expenses)	-4,220	-259.22	-7,817	-2,522	-0	-
Pretax Income	16,054	8,432	27,774	144,892	3,169	204.6
Income Tax Expense	8,302	7,822	8,688	30,301	634.14	5.69
Earnings From Continuing Operations	7,752	610.19	19,087	114,591	2,535	198.91
Minority Interest in Earnings	1.64	1.03	0.32	-0.3	-	-
Net Income	7,753	611.22	19,087	114,590	2,535	198.91
Net Income to Common	7,753	611.22	19,087	114,590	2,535	198.91
Net Income Growth	269.22%	-96.80%	-83.34%	4420.48%	1174.41%	-
Shares Outstanding (Basic)	70	71	71	71	7	1
Shares Outstanding (Diluted)	70	71	71	71	7	1
Shares Change (YoY)	-0.26%	-	0.02%	978.23%	764.75%	-
EPS (Basic)	110.00	8.65	270.09	1621.82	386.84	262.49
EPS (Diluted)	110.00	8.65	270.00	1621.82	386.84	262.49
EPS Growth	270.18%	-96.80%	-83.35%	319.25%	47.37%	-
Free Cash Flow	206,633	29,361	-52,059	-297,150	-18,750	-570.84
Free Cash Flow Per Share	2931.55	415.47	-736.65	-4205.61	-2861.34	-753.30
Gross Margin	65.96%	61.16%	59.09%	66.36%	60.38%	31.81%
Operating Margin	53.75%	44.89%	42.31%	43.81%	33.59%	6.34%
Profit Margin	6.63%	0.49%	11.29%	29.80%	26.02%	5.41%
Free Cash Flow Margin	176.57%	23.69%	-30.78%	-77.28%	-192.49%	-15.53%
EBITDA	63,847	56,723	73,116	170,564	3,517	307.53
EBITDA Margin	54.56%	45.76%	43.23%	44.36%	36.10%	8.37%
D&A For EBITDA	940.8	1,080	1,565	2,114	245.12	74.7
EBIT	62,906	55,643	71,551	168,450	3,272	232.83
EBIT Margin	53.75%	44.89%	42.31%	43.81%	33.59%	6.34%
Effective Tax Rate	51.72%	92.76%	31.28%	20.91%	20.01%	2.78%
Revenue as Reported	117,027	123,962	169,125	384,512	9,741	3,675

Updated Jan 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.